SCHEMBL3201757

SCHEMBL3201757

O=C(O)c1cc(S(=O)(=O)Cl)c(Cl)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CISD1 Q9NZ45 6/20 0.50
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA4 P22748 3/20 0.50
CA6 P23280 3/20 0.50
CA7 P43166 3/20 0.50
CA9 Q16790 3/20 0.50
CA13 Q8N1Q1 3/20 0.50
CA14 Q9ULX7 3/20 0.50
CA5B Q9Y2D0 3/20 0.50
CA3 P07451 2/20 0.50
CA5A P35218 2/20 0.50
MEN1 O00255 2/20 0.43
LMNA P02545 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 1/20 0.43
TRPV4 Q9HBA0 1/20 0.42
ATM Q13315 1/20 0.41
KEAP1 Q14145 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL397474 0.86 CA12 (0.54) CISD1CA12CA1CA2CA4
SCHEMBL3527127 0.85 CA12 (0.41) CISD1CA12CA1CA2CA4
SCHEMBL25404513 0.84 CA1 (0.53) CISD1CA12CA1CA2CA4
SCHEMBL7564592 0.84 CISD1 (0.49) CISD1CA12CA1CA2CA4
SCHEMBL2876194 0.84 CISD1 (0.72) CISD1CA12CA1CA2CA4
SCHEMBL30563542 0.84 CA1 (0.53) CISD1CA12CA1CA2CA4
SCHEMBL4716674 0.83 CA12 (0.70) CISD1CA12CA1CA2CA4
SCHEMBL31704157 0.83 CA12 (0.70) CISD1CA12CA1CA2CA4
SCHEMBL6551059 0.81 FABP4 (0.38) CISD1CA12CA1CA2CA4
SCHEMBL13544474 0.80 APP (0.50) CISD1CA12CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025215115-A1 COMPOUNDS FOR USE THE TREATMENT OF CANCER, NEURODEGENERATIVE DISEASES, PSYCHIATRIC DISORDERS, INFLAMMATION, EPILEPSY AND SEIZURES B&A ONCOMEDICAL (FR) 2025-10-16 WO disclosed
US-20220259167-A1 FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE UNIVERSITY HEALTH NETWORK (CA) 2022-08-18 US disclosed
WO-2020257940-A1 FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE UNIVERSITY HEALTH NETWORK (CA) 2020-12-30 WO disclosed
WO-2020257940-A1 FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE UNIVERSITY HEALTH NETWORK (CA) 2020-12-30 WO disclosed
US-10730828-B2 N-hydroxylsulfonamide derivatives as nitroxyl donors CARDIOXYL PHARMACEUTICALS, INC. (US) 2020-08-04 US disclosed
US-20180305304-A1 N-HYDROXYLSULFONAMIDE DERIVATIVES AS NITROXYL DONORS THE JOHNS HOPKINS UNIVERSITY 2018-10-25 US disclosed
EP-3365325-A1 N-HYDROXYLSULFONAMIDE DERIVATIVES AS NITROXYL DONORS Cardioxyl Pharmaceuticals Inc. (US) 2018-08-29 EP disclosed
WO-2017070084-A1 N-HYDROXYLSULFONAMIDE DERIVATIVES AS NITROXYL DONORS CARDIOXYL PHARMACEUTICALS, INC. (US) 2017-04-27 WO disclosed
US-20100029648-A1 11-Beta HSD1 Inhibitors XIANG JASON SHAOYUN 2010-02-04 US disclosed
US-7632838-B2 11-beta HSD1 inhibitors WYETH (US) 2009-12-15 US disclosed
CN-1372541-A Sulfonylcarboxamide derivatives, process for their preparation and their use as medicaments AVENTIS PHARMA GMBH (DE) 2002-10-02 CN disclosed
WO-2002072538-A1 IMPROVED METHOD FOR PRODUCING SULFONYL CARBOXAMIDE DERIVATIVES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-09-19 WO disclosed
EP-1218341-A1 SULFONYL CARBOXAMIDE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS Aventis Pharma Deutschland GmbH (DE) 2002-07-03 EP disclosed
US-20020072520-A1 Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-06-13 US disclosed
US-6342512-B1 ANTILIPEMIC AGENTS, ATHERIOSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-01-29 US disclosed
WO-2001016094-A1 SULFONYL CARBOXAMIDE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-03-08 WO disclosed
EP-0788494-B1 PROCESS FOR THE PREPARATION OF FUROSEMIDE PROTEOS SRL (IT) 2000-02-09 EP disclosed
US-5739361-A PHOTOCHLORINATION, SULFONATION, AMMONOLYSIS AND CONDENSATION WITH FURFURYLAMINE PROTEOS S.R.L. (IT) 1998-04-14 US disclosed
EP-0788494-A1 PROCESS FOR THE PREPARATION OF FUROSEMIDE PROTEOS S.R.L. (IT) 1997-08-13 EP disclosed
WO-1996012714-A1 PROCESS FOR THE PREPARATION OF FUROSEMIDE PROTEOS S.R.L. (IT) 1996-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029648-A1 11-Beta HSD1 Inhibitors HSD11B1, HSD3B1, HSD11B2 CISD1 252/4885CA12 3103/4885CA1 2701/4885
US-20180305304-A1 N-HYDROXYLSULFONAMIDE DERIVATIVES AS NITROXYL DONORS TNNI3, TNNT2, TNNC1 CISD1 1947/4885CA12 3219/4885CA1 2720/4885
US-10730828-B2 N-hydroxylsulfonamide derivatives as nitroxyl donors TNNI3, TNNT2, TNNC1 CISD1 1947/4885CA12 3219/4885CA1 2720/4885
US-20220259167-A1 FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE APP, AQP4, BACE1 CISD1 2432/4885CA12 1014/4885CA1 90/4885
US-20020072520-A1 Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals LIPA, CES1, SLC5A1 CISD1 2375/4885CA12 3421/4885CA1 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.